Loading…

Evaluation of methodologies to determine the effect of specific active immunotherapy on VEGF levels in phase I clinical trial patients with advanced solid tumors

Two phase I clinical trials were conducted to evaluate, among other parameters, the humoral response elicited by a vascular endothelial growth factor (VEGF)-based therapeutic vaccine in cancer patients with advanced solid tumors. VEGF reduction was studied using an indirect methodology named as “Pla...

Full description

Saved in:
Bibliographic Details
Published in:Heliyon 2018-11, Vol.4 (11), p.e00906-e00906, Article e00906
Main Authors: Sánchez Ramírez, Javier, Bequet-Romero, Mónica, Morera Díaz, Yanelys, Hernández-Bernal, Francisco, de la Torre Santos, Ana, Selman-Housein Bernal, Katty-Hind, Martín Bauta, Yenima, Bermúdez Badell, Cimara H., Limonta Fernández, Miladys, Ayala Avila, Marta
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c533t-33d93245bf0c30d89c265b1d2b59df8ebb5b764b6710fee09f570eaecbeb807f3
cites cdi_FETCH-LOGICAL-c533t-33d93245bf0c30d89c265b1d2b59df8ebb5b764b6710fee09f570eaecbeb807f3
container_end_page e00906
container_issue 11
container_start_page e00906
container_title Heliyon
container_volume 4
creator Sánchez Ramírez, Javier
Bequet-Romero, Mónica
Morera Díaz, Yanelys
Hernández-Bernal, Francisco
de la Torre Santos, Ana
Selman-Housein Bernal, Katty-Hind
Martín Bauta, Yenima
Bermúdez Badell, Cimara H.
Limonta Fernández, Miladys
Ayala Avila, Marta
description Two phase I clinical trials were conducted to evaluate, among other parameters, the humoral response elicited by a vascular endothelial growth factor (VEGF)-based therapeutic vaccine in cancer patients with advanced solid tumors. VEGF reduction was studied using an indirect methodology named as “Platelet VEGF”. This methodology is based on the estimation of VEGF within platelets by subtracting the plasma VEGF level from the serum level and dividing this by the platelet count, and then this latter expression is additionally corrected by the hematocrit. However, there is broad debate, whether serum or plasma VEGF or platelet-derived VEGF measurements is the most appropriate strategy to study the changes that occur on ligand bioavailability when patients are submitted to a VEGF-based immunotherapy. The current research is a retrospective study evaluating the changes on VEGF levels in serum and plasma as well as platelet-derived measurements. Changes in VEGF levels were related with the humoral response seen in cancer patients after an active immunotherapy with a VEGF-based vaccine. The present study indicates that “Platelet VEGF” is the most reliable methodology to investigate the effect of VEGF-based immunotherapies on ligand bioavailability. “Platelet VEGF” was associated with those groups of individuals that exhibited the best specific humoral response and the variation of “Platelet VEGF” showed the strongest negative correlation with VEGF-specific IgG antibody levels. This methodology will be very useful for the investigation of this VEGF-based vaccine in phase II clinical trials and could be applied to immunotherapies directed to other growth factors that are actively sequestered by platelets.
doi_str_mv 10.1016/j.heliyon.2018.e00906
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d0323fe1dd8d4e3986f5db7d9bee6cb4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2405844018317699</els_id><doaj_id>oai_doaj_org_article_d0323fe1dd8d4e3986f5db7d9bee6cb4</doaj_id><sourcerecordid>2133441446</sourcerecordid><originalsourceid>FETCH-LOGICAL-c533t-33d93245bf0c30d89c265b1d2b59df8ebb5b764b6710fee09f570eaecbeb807f3</originalsourceid><addsrcrecordid>eNqFks1uGyEUhUdVqyZK8witWHZjBwbmb9OqipzEUqRu2m4RPxcPFjNMgZnKj9M3La7dKFl1AwjO_Q5wT1G8J3hNMKlv9usenD34cV1i0q4B4w7Xr4rLkuFq1TKGXz9bXxTXMe4xxqRq666hb4sLillZE8wui9-bRbhZJOtH5A0aIPVee-d3FiJKHmlIEAY7Ako9IDAGVDoK4wTKGquQUMkugOwwzKPPmiCmA8qwH5v7O-RgAReRHdHUiwhoi5Szo1XCoRRsHqfsDGOK6JdNPRJ6EaMCjaJ3VqM0Dz7Ed8UbI1yE6_N8VXy_23y7fVg9fr3f3n55XKmK0rSiVHe0ZJU0WFGs206VdSWJLmXVadOClJVsaibrhmADgDtTNRgEKAmyxY2hV8X2xNVe7PkU7CDCgXth-d8NH3ZchGSVA64xLakBonWrGdCurU2lZaM7CVAryTLr04k1zXIArfITg3AvoC9PRtvznV94XZaUtF0GfDwDgv85Q0x8sFGBc2IEP0deEkoZI4zVWVqdpCr4GAOYJxuC-TEtfM_PaeHHtPBTWnLdh-d3fKr6l40s-HwS5BbCYiHwqHKzcn9syCnI32L_Y_EHGA7ZVQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2133441446</pqid></control><display><type>article</type><title>Evaluation of methodologies to determine the effect of specific active immunotherapy on VEGF levels in phase I clinical trial patients with advanced solid tumors</title><source>ScienceDirect®</source><source>PubMed Central</source><creator>Sánchez Ramírez, Javier ; Bequet-Romero, Mónica ; Morera Díaz, Yanelys ; Hernández-Bernal, Francisco ; de la Torre Santos, Ana ; Selman-Housein Bernal, Katty-Hind ; Martín Bauta, Yenima ; Bermúdez Badell, Cimara H. ; Limonta Fernández, Miladys ; Ayala Avila, Marta</creator><creatorcontrib>Sánchez Ramírez, Javier ; Bequet-Romero, Mónica ; Morera Díaz, Yanelys ; Hernández-Bernal, Francisco ; de la Torre Santos, Ana ; Selman-Housein Bernal, Katty-Hind ; Martín Bauta, Yenima ; Bermúdez Badell, Cimara H. ; Limonta Fernández, Miladys ; Ayala Avila, Marta</creatorcontrib><description>Two phase I clinical trials were conducted to evaluate, among other parameters, the humoral response elicited by a vascular endothelial growth factor (VEGF)-based therapeutic vaccine in cancer patients with advanced solid tumors. VEGF reduction was studied using an indirect methodology named as “Platelet VEGF”. This methodology is based on the estimation of VEGF within platelets by subtracting the plasma VEGF level from the serum level and dividing this by the platelet count, and then this latter expression is additionally corrected by the hematocrit. However, there is broad debate, whether serum or plasma VEGF or platelet-derived VEGF measurements is the most appropriate strategy to study the changes that occur on ligand bioavailability when patients are submitted to a VEGF-based immunotherapy. The current research is a retrospective study evaluating the changes on VEGF levels in serum and plasma as well as platelet-derived measurements. Changes in VEGF levels were related with the humoral response seen in cancer patients after an active immunotherapy with a VEGF-based vaccine. The present study indicates that “Platelet VEGF” is the most reliable methodology to investigate the effect of VEGF-based immunotherapies on ligand bioavailability. “Platelet VEGF” was associated with those groups of individuals that exhibited the best specific humoral response and the variation of “Platelet VEGF” showed the strongest negative correlation with VEGF-specific IgG antibody levels. This methodology will be very useful for the investigation of this VEGF-based vaccine in phase II clinical trials and could be applied to immunotherapies directed to other growth factors that are actively sequestered by platelets.</description><identifier>ISSN: 2405-8440</identifier><identifier>EISSN: 2405-8440</identifier><identifier>DOI: 10.1016/j.heliyon.2018.e00906</identifier><identifier>PMID: 30426104</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Cancer research ; Immunology</subject><ispartof>Heliyon, 2018-11, Vol.4 (11), p.e00906-e00906, Article e00906</ispartof><rights>2018 The Authors</rights><rights>2018 The Authors 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c533t-33d93245bf0c30d89c265b1d2b59df8ebb5b764b6710fee09f570eaecbeb807f3</citedby><cites>FETCH-LOGICAL-c533t-33d93245bf0c30d89c265b1d2b59df8ebb5b764b6710fee09f570eaecbeb807f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223189/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2405844018317699$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3549,27924,27925,45780,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30426104$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sánchez Ramírez, Javier</creatorcontrib><creatorcontrib>Bequet-Romero, Mónica</creatorcontrib><creatorcontrib>Morera Díaz, Yanelys</creatorcontrib><creatorcontrib>Hernández-Bernal, Francisco</creatorcontrib><creatorcontrib>de la Torre Santos, Ana</creatorcontrib><creatorcontrib>Selman-Housein Bernal, Katty-Hind</creatorcontrib><creatorcontrib>Martín Bauta, Yenima</creatorcontrib><creatorcontrib>Bermúdez Badell, Cimara H.</creatorcontrib><creatorcontrib>Limonta Fernández, Miladys</creatorcontrib><creatorcontrib>Ayala Avila, Marta</creatorcontrib><title>Evaluation of methodologies to determine the effect of specific active immunotherapy on VEGF levels in phase I clinical trial patients with advanced solid tumors</title><title>Heliyon</title><addtitle>Heliyon</addtitle><description>Two phase I clinical trials were conducted to evaluate, among other parameters, the humoral response elicited by a vascular endothelial growth factor (VEGF)-based therapeutic vaccine in cancer patients with advanced solid tumors. VEGF reduction was studied using an indirect methodology named as “Platelet VEGF”. This methodology is based on the estimation of VEGF within platelets by subtracting the plasma VEGF level from the serum level and dividing this by the platelet count, and then this latter expression is additionally corrected by the hematocrit. However, there is broad debate, whether serum or plasma VEGF or platelet-derived VEGF measurements is the most appropriate strategy to study the changes that occur on ligand bioavailability when patients are submitted to a VEGF-based immunotherapy. The current research is a retrospective study evaluating the changes on VEGF levels in serum and plasma as well as platelet-derived measurements. Changes in VEGF levels were related with the humoral response seen in cancer patients after an active immunotherapy with a VEGF-based vaccine. The present study indicates that “Platelet VEGF” is the most reliable methodology to investigate the effect of VEGF-based immunotherapies on ligand bioavailability. “Platelet VEGF” was associated with those groups of individuals that exhibited the best specific humoral response and the variation of “Platelet VEGF” showed the strongest negative correlation with VEGF-specific IgG antibody levels. This methodology will be very useful for the investigation of this VEGF-based vaccine in phase II clinical trials and could be applied to immunotherapies directed to other growth factors that are actively sequestered by platelets.</description><subject>Cancer research</subject><subject>Immunology</subject><issn>2405-8440</issn><issn>2405-8440</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqFks1uGyEUhUdVqyZK8witWHZjBwbmb9OqipzEUqRu2m4RPxcPFjNMgZnKj9M3La7dKFl1AwjO_Q5wT1G8J3hNMKlv9usenD34cV1i0q4B4w7Xr4rLkuFq1TKGXz9bXxTXMe4xxqRq666hb4sLillZE8wui9-bRbhZJOtH5A0aIPVee-d3FiJKHmlIEAY7Ako9IDAGVDoK4wTKGquQUMkugOwwzKPPmiCmA8qwH5v7O-RgAReRHdHUiwhoi5Szo1XCoRRsHqfsDGOK6JdNPRJ6EaMCjaJ3VqM0Dz7Ed8UbI1yE6_N8VXy_23y7fVg9fr3f3n55XKmK0rSiVHe0ZJU0WFGs206VdSWJLmXVadOClJVsaibrhmADgDtTNRgEKAmyxY2hV8X2xNVe7PkU7CDCgXth-d8NH3ZchGSVA64xLakBonWrGdCurU2lZaM7CVAryTLr04k1zXIArfITg3AvoC9PRtvznV94XZaUtF0GfDwDgv85Q0x8sFGBc2IEP0deEkoZI4zVWVqdpCr4GAOYJxuC-TEtfM_PaeHHtPBTWnLdh-d3fKr6l40s-HwS5BbCYiHwqHKzcn9syCnI32L_Y_EHGA7ZVQ</recordid><startdate>20181101</startdate><enddate>20181101</enddate><creator>Sánchez Ramírez, Javier</creator><creator>Bequet-Romero, Mónica</creator><creator>Morera Díaz, Yanelys</creator><creator>Hernández-Bernal, Francisco</creator><creator>de la Torre Santos, Ana</creator><creator>Selman-Housein Bernal, Katty-Hind</creator><creator>Martín Bauta, Yenima</creator><creator>Bermúdez Badell, Cimara H.</creator><creator>Limonta Fernández, Miladys</creator><creator>Ayala Avila, Marta</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20181101</creationdate><title>Evaluation of methodologies to determine the effect of specific active immunotherapy on VEGF levels in phase I clinical trial patients with advanced solid tumors</title><author>Sánchez Ramírez, Javier ; Bequet-Romero, Mónica ; Morera Díaz, Yanelys ; Hernández-Bernal, Francisco ; de la Torre Santos, Ana ; Selman-Housein Bernal, Katty-Hind ; Martín Bauta, Yenima ; Bermúdez Badell, Cimara H. ; Limonta Fernández, Miladys ; Ayala Avila, Marta</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c533t-33d93245bf0c30d89c265b1d2b59df8ebb5b764b6710fee09f570eaecbeb807f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Cancer research</topic><topic>Immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sánchez Ramírez, Javier</creatorcontrib><creatorcontrib>Bequet-Romero, Mónica</creatorcontrib><creatorcontrib>Morera Díaz, Yanelys</creatorcontrib><creatorcontrib>Hernández-Bernal, Francisco</creatorcontrib><creatorcontrib>de la Torre Santos, Ana</creatorcontrib><creatorcontrib>Selman-Housein Bernal, Katty-Hind</creatorcontrib><creatorcontrib>Martín Bauta, Yenima</creatorcontrib><creatorcontrib>Bermúdez Badell, Cimara H.</creatorcontrib><creatorcontrib>Limonta Fernández, Miladys</creatorcontrib><creatorcontrib>Ayala Avila, Marta</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Heliyon</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sánchez Ramírez, Javier</au><au>Bequet-Romero, Mónica</au><au>Morera Díaz, Yanelys</au><au>Hernández-Bernal, Francisco</au><au>de la Torre Santos, Ana</au><au>Selman-Housein Bernal, Katty-Hind</au><au>Martín Bauta, Yenima</au><au>Bermúdez Badell, Cimara H.</au><au>Limonta Fernández, Miladys</au><au>Ayala Avila, Marta</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of methodologies to determine the effect of specific active immunotherapy on VEGF levels in phase I clinical trial patients with advanced solid tumors</atitle><jtitle>Heliyon</jtitle><addtitle>Heliyon</addtitle><date>2018-11-01</date><risdate>2018</risdate><volume>4</volume><issue>11</issue><spage>e00906</spage><epage>e00906</epage><pages>e00906-e00906</pages><artnum>e00906</artnum><issn>2405-8440</issn><eissn>2405-8440</eissn><abstract>Two phase I clinical trials were conducted to evaluate, among other parameters, the humoral response elicited by a vascular endothelial growth factor (VEGF)-based therapeutic vaccine in cancer patients with advanced solid tumors. VEGF reduction was studied using an indirect methodology named as “Platelet VEGF”. This methodology is based on the estimation of VEGF within platelets by subtracting the plasma VEGF level from the serum level and dividing this by the platelet count, and then this latter expression is additionally corrected by the hematocrit. However, there is broad debate, whether serum or plasma VEGF or platelet-derived VEGF measurements is the most appropriate strategy to study the changes that occur on ligand bioavailability when patients are submitted to a VEGF-based immunotherapy. The current research is a retrospective study evaluating the changes on VEGF levels in serum and plasma as well as platelet-derived measurements. Changes in VEGF levels were related with the humoral response seen in cancer patients after an active immunotherapy with a VEGF-based vaccine. The present study indicates that “Platelet VEGF” is the most reliable methodology to investigate the effect of VEGF-based immunotherapies on ligand bioavailability. “Platelet VEGF” was associated with those groups of individuals that exhibited the best specific humoral response and the variation of “Platelet VEGF” showed the strongest negative correlation with VEGF-specific IgG antibody levels. This methodology will be very useful for the investigation of this VEGF-based vaccine in phase II clinical trials and could be applied to immunotherapies directed to other growth factors that are actively sequestered by platelets.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>30426104</pmid><doi>10.1016/j.heliyon.2018.e00906</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2405-8440
ispartof Heliyon, 2018-11, Vol.4 (11), p.e00906-e00906, Article e00906
issn 2405-8440
2405-8440
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_d0323fe1dd8d4e3986f5db7d9bee6cb4
source ScienceDirect®; PubMed Central
subjects Cancer research
Immunology
title Evaluation of methodologies to determine the effect of specific active immunotherapy on VEGF levels in phase I clinical trial patients with advanced solid tumors
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T13%3A30%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20methodologies%20to%20determine%20the%20effect%20of%20specific%20active%20immunotherapy%20on%20VEGF%20levels%20in%20phase%20I%20clinical%20trial%20patients%20with%20advanced%20solid%20tumors&rft.jtitle=Heliyon&rft.au=S%C3%A1nchez%20Ram%C3%ADrez,%20Javier&rft.date=2018-11-01&rft.volume=4&rft.issue=11&rft.spage=e00906&rft.epage=e00906&rft.pages=e00906-e00906&rft.artnum=e00906&rft.issn=2405-8440&rft.eissn=2405-8440&rft_id=info:doi/10.1016/j.heliyon.2018.e00906&rft_dat=%3Cproquest_doaj_%3E2133441446%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c533t-33d93245bf0c30d89c265b1d2b59df8ebb5b764b6710fee09f570eaecbeb807f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2133441446&rft_id=info:pmid/30426104&rfr_iscdi=true